Adam Olszewski MD

Lymphoma oncologist at Brown University / Rhode Island Hospital

[The Lancet Haematology @TheLancetHaem]

New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
https://t.co/74MH7fEAn6

[Katharine Lewis @Dr_KatLewis]

Delighted to share our work now published on behalf of all co-authors.

Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL.

Thank you so much to all international collaborators!
https://t.co/3yjHqH3dap

[Adam Olszewski MD @lymphomatic]

For systemic #CTCL /MF/SS, @BrownHeme we choose #immunotherapy a lot. Reviewing T-cell containment options: kill'em, poison'em, PD1-knock'em. But really we should be turning them against each other... https://t.co/p3DHqmSQBS @OllilaTom #lymsm

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

🙌TY to all collaborators (@sairah__ahmed, @LNastoupilMD, @uroosaibrahim, @NEpperla, @tvoorheesmd, @lymphomatic etc) & @RutgersCancer fellow Dr McKenna on this #RWE of #CART for rel/ref SOT-PTLD. We describe immunosupression, toxicity & outcomes. @BrJHaem

https://t.co/rtqoJyShUr

[Liz Brem, MD @DrLizBrem]

East coast friends! @JohnPLeonardMD gave @lymphomatic and I the challenge of debating the utility of CNS prophylaxis in DLBCL. Come learn and watch us duke it out on 04/13 in NYC! Register now: https://t.co/38tvDlUZHb @GreatDebatesCME #bloodcancer #HematologicMalignancies

[Mengyang Di, MD PhD @DiMengyang]

Check out our study on function, treatment, and outcomes in nursing home patients w/ DLBCL- a population very challenging to manage!
Glad to see this published. This concludes a series of projects on older pts w/ aggressive lymphoma that are very close to my heart! @lymphomatic

[Adam Olszewski MD @lymphomatic]

@DrLizBrem and I have been working towards figuring out how to solve the conundrum of CNS prophylaxis in #DLBCL through clinical research. It will be great to spar (gently) with arguments pro and con in this @GreatDebatesCME #lymsm

[OLN Great Debates in Solid Tumors @OLNGreatDebates]

Learn from the very best in the field – including local faculty right here in the tri-state area. Register now & save: https://t.co/jdDa7Qd1rd

#GDUHEM #HematologicMalignancies @JohnPLeonardMD
@WeillCornell @lymphomatic @DrCarlaCasulo @WilmotCancer @UR_Med @northwesternmed

[Adam Olszewski MD @lymphomatic]

@CharlesMilrod @Jmarksloan @PeterBarthMD @AaronGoodman33 @nihardesai7 @OllilaTom @BrownHospMed @myelomatic @tony_breu @vsanchorawala It is a great poke to unlearn the "leukostasis = leukopheresis" knee-jerk reaction from your board course. Sad this is an area where citations are from the last century.

[Blood Journals Portfolio @BloodPortfolio]

Editorial: The demise of Roe v Wade: a hematologist’s perspective https://t.co/h85d7TXep1

[Adam Olszewski MD @lymphomatic]

@hemepathguy @DrAEvens We talk about it in the paper!

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

Defining and treating high-grade B-cell #lymphoma, NOS https://t.co/lderjcWpWx

TY to @BrownMedicine @lymphomatic & @BrownUniversity Dr Kurt collab on this review.

2 new classifications out since this was pre-published ~1 year ago but most content still valid/relevant!

#lymsm

[Adam Olszewski MD @lymphomatic]

@DrAEvens @BrownMedicine @BrownUniversity The HGBL now includes “HGBL with 11q aberration” and HGBL with MYC & BCL6 rearrangements. Welcome to the (still “heterogenous and poorly defined”) family!

[ACS Journal Cancer @JournalCancer]

#COVID19 booster vaccination leads to seroconversion in over 1/2 of patients w/ hematologic malignancies who had undetectable antibodies to the initial vaccine series. The risk of death appears highest in those with undetectable antibodies. https://t.co/7kZwkxK5Is @OncoAlert

[Adam Olszewski MD @lymphomatic]

#boosters work for >50% of pts with #lymphoma who did not respond to initial vaccine. On or off treatment. Boosters + #Evusheld have largely eliminated #COVID deaths (in our center) #lymsm @JournalCancer @ASH_hematology https://t.co/TTLdS2wQOD

[BioAscend @BioAscend]

Register at https://t.co/UIDchY830q to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, @lymphomatic, Dr. Neha Mehta-Shah & Dr. Dan Landsburg at #IUCLS2022! Join us live in Chicago April 29-30! @UChicagoCME

[Adam Olszewski MD @lymphomatic]

@DiMengyang @sfhYALE @Dr_AmerZeidan Fourth ASH means you now need to start mentoring too!

[Adam Olszewski MD @lymphomatic]

We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? https://t.co/AJ9S3VCXpV #lymsm @BloodAdvances @AdaptiveBiotech @BrownHeme

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal @ASH_hematology https://t.co/zO87mZ7tkj

Happy to publish this review w/ @RIHospital @BrownUCancer @lymphomatic & Dr Kurt on the challenging topic/entity of HGBL-NOS (1st pic below is correct Fig 1). #lymsm

[Matthew Davids, MD, MMSc @DrMDavids]

The future of CLL therapy has arrived: our ph2 AVO trial in 1L CLL from @DanaFarber and @BIDMChealth with support from @AstraZeneca and @genentech is now online @TheLancetOncol https://t.co/RiRZZ8rhj1

[Adam Olszewski MD @lymphomatic]

@DusetzinaS You have seven days. Including the weekend.